Management of Desmoids

Valerie P Grignol; Raphael Pollock; John Harrison Howard

doi:10.1016/j.suc.2016.05.008

Management of Desmoids

Surg Clin North Am. 2016 Oct;96(5):1015-30. doi: 10.1016/j.suc.2016.05.008.

Authors

Valerie P Grignol¹, Raphael Pollock¹, John Harrison Howard²

Affiliations

¹ Division of Surgical Oncology, Department of Surgery, The Ohio State University, N924 Doan Hall, 410 West 10th Avenue, Columbus, OH 43210, USA.
² Division of Surgical Oncology, Department of Surgery, The Ohio State University, N924 Doan Hall, 410 West 10th Avenue, Columbus, OH 43210, USA. Electronic address: John.Howard@osumc.edu.

PMID: 27542640
DOI: 10.1016/j.suc.2016.05.008

Abstract

Desmoid tumors are rare, comprising 3% of soft tissue tumors. Surgical resection has been the standard of care; however, this has begun to evolve into a movement of watchful waiting as observational studies have shown long-term stability of many tumors without treatment and even spontaneous regression in 5% to 10% of cases. When surgical therapy is used, wide local excision with microscopically negative margins is the goal of resection but should not be at the expense of organ or limb function. Recurrence rates after surgical resection are approximately 20%; a variety of multimodal therapies are useful in controlling disease.

Keywords: Beta-catenin; Desmoid fibromatosis; Management; Margins; Observation.

Publication types

Review

MeSH terms

Combined Modality Therapy
Disease Management*
Fibromatosis, Aggressive / therapy*
Humans